MedTrace Logo

Bevacizumab Versus DEX Implant Followed by Bevacizumab in ME Secondary to BRVO

NCT03892434 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-03-27

No results posted yet for this study

Summary

To evaluate the efficacy of sequential therapy with intravitreal dexamethasone implant followed by bevacizumab compared with bevacizumab monotherapy for macular edema (ME) secondary to retinal vein occlusion (RVO).

Conditions

  • Branch Retinal Vein Occlusion With Macular Edema

Interventions

DRUG

Intravitreal bevacizumab and dexamethasone implant Injection

Bevacizumab 1.25mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion, and Dexamethasone 0.75mg implant is injected using injector.

DEVICE

Intravitreal dexamethasone implant

Dexamethasone implant insertion using approved kit

Sponsors & Collaborators

  • Yeungnam University College of Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-18
Primary Completion
2019-12-18
Completion
2020-06-18
FDA Drug
Yes
FDA Device
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03892434 on ClinicalTrials.gov